Results Healthcare has provided strategic support to Horizon Therapeutics resulting in the acquisition of a facility from EirGen Pharma

  • Service: Strategic Advice
  • Sector: Healthcare
  • Sub Sector: CROs & CMOs, Pharma & Biotech
  • Engagement Type: Buy Side
Jun 2021
has acquired a drug product manufacturing facility from

Results Healthcare is delighted to announce that it has provided strategic support to Horizon Therapeutics, a biotechnology company focused on rare, autoimmune diseases, that resulted in its acquisition of a drug product manufacturing facility from EirGen Pharma, in Ireland.

Under the terms of the agreement, Horizon will acquire the facility for a $65 million upfront cash payment. In addition, there is adjacent IDA land available for further manufacturing and development expansion. The transaction, which is subject to customary closing conditions, is expected to close in the third quarter.

This transaction represents our x deal in the biotechnology sector in the last 24 months and is a testament to our deep sector knowledge and industry relationships.

Tim Walbert, chairman, president and chief executive officer, Horizon

“Adding to our strong network of contract manufacturing organizations, this facility will also play an important role in our global expansion. We look forward to leveraging our existing technical operations expertise in Ireland, along with the expertise of the EirGen employees, to build a robust and effective manufacturing operation that will enable us to meet the unmet needs of people impacted by rare diseases around the world.”

Sector Related Deals

May 2022
A subsidiary of Servier
has divested its anti-LAG-3 monocloncal antibody to
A subsidiary of Sino Biopharmaceutical Limited
Mar 2022
has divested its Ringaskiddy, Ireland, manufacturing facility
Mar 2022
has divested its Boucherville, Canada manufacturing facility
Jan 2022
has divested its API manufacturing site in Cramlington, UK, to
Nov 2021
has made an investment in
company name confidential
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
May 2021
has been acquired by
a Behrman Capital-backed company
May 2021
has formed a strategic alliance with
Mar 2021
has licensed the patents and know-how to its Crystalomics Formulation Technology to